A bittersweet moment as the industry congratulates our longtime colleague and collaborator, Nick Green, on a well-deserved retirement.
A bittersweet moment as the industry congratulates our longtime colleague and collaborator, Nick Green, on a well-deserved retirement.
It was a pleasure to visit such a well-run GLP lab at FairJourney Biologics’ headquarters in Porto, Portugal.
A fascinating presentation from Dr. Hollanbaugh, highlighting the discussion around Interleukin-2 (IL-2) inhibitors, which have emerged as a pivotal class of therapeutic agents, particularly in the realm of immunology and oncology.
Day Two of TAS25 kicks off with a presentation by Professor Madelon Maurice from the Madelon Maurice Lab in Holland.
Peter Senter, Ph.D., Janine Schuurman, Ph.D., and Greg Thurber, Ph.D. — now that’s a lineup.
Peter Senter, Ph.D., is the keynote for TAS25. Peter joined Seattle Genetics in 1998 and was part of the research team focused on anticancer therapies before the company’s $43 billion sale to Pfizer in 2023.
So grateful to the team at FairJourney Biologics for inviting our team to TAS25, their high-science discovery show in Porto, Portugal.
That’s Nice is visiting the FairJourney Biologics facilities in Porto, Portugal, as a kick-off to TAS2025: The Anti-Body Series.
Exciting to be able to check out the expanded construction at IDT’s facility in Germany.
Thanks to everyone who made this year at BIO one of the best yet, both on the Spirit of Boston for our 30th anniversary bash and at the Boston Convention Center for the show itself. We’re so excited for what’s in store for the second half of 2025!